Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial.

about

Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial.

Item

http://www.wikidata.org/entity/Q47309233

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Campath, calcineurin inhibitor ...... zed controlled clinical trial.

@en

Campath, calcineurin inhibitor ...... zed controlled clinical trial.

@nl

type

Item

label

Campath, calcineurin inhibitor ...... zed controlled clinical trial.

@en

Campath, calcineurin inhibitor ...... zed controlled clinical trial.

@nl

prefLabel

Campath, calcineurin inhibitor ...... zed controlled clinical trial.

@en

Campath, calcineurin inhibitor ...... zed controlled clinical trial.

@nl

P1476

Campath, calcineurin inhibitor ...... zed controlled clinical trial.

@en

P2093

3C Study Collaborative Group

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data.

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.

Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature.

Chronic progressive calcineurin nephrotoxicity: an overstated concept.

P304

1424-1434

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/AJT.14619

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29226570

http://www.w3.org/2001/XMLSchema#string

P932

6001618

http://www.w3.org/2001/XMLSchema#string